From prevention to treatment, Meiji is improving quality of care and lowering drug costs for millions of patients worldwide.
Medical needs are always changing, and Meiji is responding with new drug development for infectious diseases and other conditions. We also engage in open innovation in fields such as hematology and oncology.
Our development pipeline ranges from areas of core expertise through to biosimilars and generic drugs for blood tumors.
Beginning with the production of penicillin in 1946, Meiji Seika Pharma has established itself as a leader in the manufacture and sale of antibacterial drugs. The company also supplies high-quality generic drugs and treatments.
Corporate Profile
Get to know Meiji at a glance, from our core business to our most important numbers – plus what's in store for our next 100 years.
Our new group slogan puts wellness at the heart of everything we do.
The Meiji Group promotes innovation through a unique synergy between food and pharmaceutical expertise.